Monopar Therapeutics Reports Q1 2026 Financial Results and Updates
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy MNPR?
Source: Yahoo Finance
- Program Development: Monopar presented findings on ALXN1840's clinical benefits for Wilson disease patients at the AAN Annual Meeting in April 2026, with plans to submit a New Drug Application (NDA) by mid-2026, which could facilitate future market access for the drug.
- Financial Position: As of March 31, 2026, Monopar reported cash and investments totaling $137.5 million, which is expected to support operations through December 2027, indicating strong financial management and operational sustainability.
- Net Loss Overview: The company reported a net loss of $3.9 million for Q1 2026, translating to a loss of $0.46 per share, which is an increase from the $2.6 million loss in Q1 2025, reflecting ongoing investments in research and development.
- R&D Expense Increase: R&D expenses surged to $3.5 million in Q1 2026 from $1.6 million in the same period last year, primarily due to rising contractor and personnel costs, highlighting Monopar's commitment to advancing its drug development pipeline.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MNPR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MNPR
Wall Street analysts forecast MNPR stock price to rise
11 Analyst Rating
11 Buy
0 Hold
0 Sell
Strong Buy
Current: 60.990
Low
95.00
Averages
112.91
High
130.00
Current: 60.990
Low
95.00
Averages
112.91
High
130.00
About MNPR
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Monopar Therapeutics Reports Q1 2026 Financial Results and Updates
- Program Development: Monopar presented findings on ALXN1840's clinical benefits for Wilson disease patients at the AAN Annual Meeting in April 2026, with plans to submit a New Drug Application (NDA) by mid-2026, which could facilitate future market access for the drug.
- Financial Position: As of March 31, 2026, Monopar reported cash and investments totaling $137.5 million, which is expected to support operations through December 2027, indicating strong financial management and operational sustainability.
- Net Loss Overview: The company reported a net loss of $3.9 million for Q1 2026, translating to a loss of $0.46 per share, which is an increase from the $2.6 million loss in Q1 2025, reflecting ongoing investments in research and development.
- R&D Expense Increase: R&D expenses surged to $3.5 million in Q1 2026 from $1.6 million in the same period last year, primarily due to rising contractor and personnel costs, highlighting Monopar's commitment to advancing its drug development pipeline.
See More
Monopar Therapeutics Q1 Earnings Beat Expectations
- Earnings Performance: Monopar Therapeutics reported a Q1 GAAP EPS of -$0.46, beating expectations by $0.36, indicating improved financial management that could bolster investor confidence.
- Strong Cash Reserves: As of March 31, 2026, Monopar holds $137.5 million in cash, cash equivalents, and investments, ensuring sufficient operational funding for at least the next two years to support its R&D and commercial activities.
- Clear Funding Utilization Plan: The company expects its current funds to sustain operations through December 31, 2027, covering regulatory and potential commercial activities for ALXN1840, continued development of MNPR-101 programs, and internal R&D, reflecting a well-defined strategic plan.
- Ongoing R&D Commitment: Monopar will continue to advance the development of the MNPR-101 program, demonstrating its strong commitment to innovative drug development, which may establish a competitive edge in the market.
See More
Monopar Therapeutics Reports Q1 2026 Financial Results and Updates
- Financial Overview: As of March 31, 2026, Monopar's cash and cash equivalents stood at $137.5 million, which is expected to support operations through December 31, 2027, ensuring funding for future R&D and commercial activities.
- R&D Expense Increase: R&D expenses for Q1 2026 reached $3.487 million, a 112.5% increase from $1.643 million in Q1 2025, primarily due to significant rises in contractor and personnel costs, reflecting the company's ongoing commitment to drug development.
- Net Loss Situation: The net loss for Q1 2026 was $3.9 million, or $0.46 per share, compared to a net loss of $2.6 million and $0.38 per share in Q1 2025, indicating higher costs associated with expanding R&D and market readiness efforts.
- Interest Income Growth: Interest income for Q1 2026 was $1.332 million, up 123% from $596,845 in Q1 2025, primarily driven by increased earnings from U.S. Treasury securities and commercial paper, showcasing effective financial management by the company.
See More
Monopar Releases New Analysis Data on ALXN1840
- Clinical Trial Results: In the randomized controlled FoCus trial, ALXN1840 demonstrated significant neurologic improvement in Wilson disease patients, with 45% of treated patients achieving clinically meaningful improvement at Week 48 compared to only 32% in the standard care group, indicating ALXN1840's potential to address critical unmet medical needs.
- Reduced Worsening Rates: At Week 48, clinically meaningful neurologic worsening was observed in 25% of patients receiving standard care versus only 9% in the ALXN1840 group (p=0.038), highlighting not only the efficacy of ALXN1840 but also its potential to transform the treatment landscape for Wilson disease.
- Sustained Long-term Efficacy: The neurologic benefits of ALXN1840 continued to increase during long-term follow-up, with a median treatment duration of 2.58 years and a maximum exceeding 8 years, indicating a favorable safety and tolerability profile for long-term use.
- FDA Application Plans: These positive clinical results support Monopar's planned New Drug Application (NDA) submission to the U.S. FDA in mid-2026, which will provide new treatment options for Wilson disease patients and further enhance the company's market position.
See More
Monopar Therapeutics Reports Q4 Earnings Miss
- Earnings Report Disappointment: Monopar Therapeutics reported a Q4 GAAP EPS of -$0.61, missing expectations by $0.16, indicating challenges in profitability that may affect investor confidence.
- Cash Position Overview: As of December 31, 2025, the company had $140.4 million in cash, cash equivalents, and short-term investments, which, while providing some liquidity, raises concerns about capital efficiency and future funding needs.
- Market Reaction Analysis: The earnings miss has led to market concerns regarding Monopar's growth potential, likely putting downward pressure on the stock price and impacting its competitive position in the biopharmaceutical sector.
- Investor Focus: Analysts' quant ratings on Monopar Therapeutics reflect market scrutiny over its financial health, prompting investors to closely monitor future financial performance and strategic adjustments.
See More
Monopar Reports 2025 Financial Results and Drug Development Updates
- Financial Performance Boost: Monopar completed an underwritten public offering generating approximately $91.9 million in 2025, significantly strengthening its balance sheet, with current funds expected to support operations through December 31, 2027, ensuring smooth regulatory and commercial activities for ALXN1840.
- Significant R&D Progress: The NDA for ALXN1840 targeting Wilson disease is planned for submission in mid-2026, with recent presentations at EASL and ANA showcasing long-term efficacy and safety data from 255 patients, indicating statistically significant improvements in copper balance.
- Leadership Team Strengthening: Monopar appointed Susan Rodriguez as Chief Commercial and Strategy Officer to prepare for the potential launch of ALXN1840, further enhancing the company's competitive position in the Wilson disease treatment market.
- R&D Expense Control: R&D expenses for Q4 2025 were $3.9 million, significantly down from $9.9 million in Q4 2024, primarily due to the absence of one-time costs, while reflecting increased investments in personnel and clinical materials.
See More
Monopar Therapeutics Reports Q1 2026 Financial Results and Updates
- Program Development: Monopar presented findings on ALXN1840's clinical benefits for Wilson disease patients at the AAN Annual Meeting in April 2026, with plans to submit a New Drug Application (NDA) by mid-2026, which could facilitate future market access for the drug.
- Financial Position: As of March 31, 2026, Monopar reported cash and investments totaling $137.5 million, which is expected to support operations through December 2027, indicating strong financial management and operational sustainability.
- Net Loss Overview: The company reported a net loss of $3.9 million for Q1 2026, translating to a loss of $0.46 per share, which is an increase from the $2.6 million loss in Q1 2025, reflecting ongoing investments in research and development.
- R&D Expense Increase: R&D expenses surged to $3.5 million in Q1 2026 from $1.6 million in the same period last year, primarily due to rising contractor and personnel costs, highlighting Monopar's commitment to advancing its drug development pipeline.
See More
Monopar Therapeutics Q1 Earnings Beat Expectations
- Earnings Performance: Monopar Therapeutics reported a Q1 GAAP EPS of -$0.46, beating expectations by $0.36, indicating improved financial management that could bolster investor confidence.
- Strong Cash Reserves: As of March 31, 2026, Monopar holds $137.5 million in cash, cash equivalents, and investments, ensuring sufficient operational funding for at least the next two years to support its R&D and commercial activities.
- Clear Funding Utilization Plan: The company expects its current funds to sustain operations through December 31, 2027, covering regulatory and potential commercial activities for ALXN1840, continued development of MNPR-101 programs, and internal R&D, reflecting a well-defined strategic plan.
- Ongoing R&D Commitment: Monopar will continue to advance the development of the MNPR-101 program, demonstrating its strong commitment to innovative drug development, which may establish a competitive edge in the market.
See More
Monopar Therapeutics Reports Q1 2026 Financial Results and Updates
- Financial Overview: As of March 31, 2026, Monopar's cash and cash equivalents stood at $137.5 million, which is expected to support operations through December 31, 2027, ensuring funding for future R&D and commercial activities.
- R&D Expense Increase: R&D expenses for Q1 2026 reached $3.487 million, a 112.5% increase from $1.643 million in Q1 2025, primarily due to significant rises in contractor and personnel costs, reflecting the company's ongoing commitment to drug development.
- Net Loss Situation: The net loss for Q1 2026 was $3.9 million, or $0.46 per share, compared to a net loss of $2.6 million and $0.38 per share in Q1 2025, indicating higher costs associated with expanding R&D and market readiness efforts.
- Interest Income Growth: Interest income for Q1 2026 was $1.332 million, up 123% from $596,845 in Q1 2025, primarily driven by increased earnings from U.S. Treasury securities and commercial paper, showcasing effective financial management by the company.
See More
Monopar Releases New Analysis Data on ALXN1840
- Clinical Trial Results: In the randomized controlled FoCus trial, ALXN1840 demonstrated significant neurologic improvement in Wilson disease patients, with 45% of treated patients achieving clinically meaningful improvement at Week 48 compared to only 32% in the standard care group, indicating ALXN1840's potential to address critical unmet medical needs.
- Reduced Worsening Rates: At Week 48, clinically meaningful neurologic worsening was observed in 25% of patients receiving standard care versus only 9% in the ALXN1840 group (p=0.038), highlighting not only the efficacy of ALXN1840 but also its potential to transform the treatment landscape for Wilson disease.
- Sustained Long-term Efficacy: The neurologic benefits of ALXN1840 continued to increase during long-term follow-up, with a median treatment duration of 2.58 years and a maximum exceeding 8 years, indicating a favorable safety and tolerability profile for long-term use.
- FDA Application Plans: These positive clinical results support Monopar's planned New Drug Application (NDA) submission to the U.S. FDA in mid-2026, which will provide new treatment options for Wilson disease patients and further enhance the company's market position.
See More
Monopar Therapeutics Reports Q4 Earnings Miss
- Earnings Report Disappointment: Monopar Therapeutics reported a Q4 GAAP EPS of -$0.61, missing expectations by $0.16, indicating challenges in profitability that may affect investor confidence.
- Cash Position Overview: As of December 31, 2025, the company had $140.4 million in cash, cash equivalents, and short-term investments, which, while providing some liquidity, raises concerns about capital efficiency and future funding needs.
- Market Reaction Analysis: The earnings miss has led to market concerns regarding Monopar's growth potential, likely putting downward pressure on the stock price and impacting its competitive position in the biopharmaceutical sector.
- Investor Focus: Analysts' quant ratings on Monopar Therapeutics reflect market scrutiny over its financial health, prompting investors to closely monitor future financial performance and strategic adjustments.
See More
Monopar Reports 2025 Financial Results and Drug Development Updates
- Financial Performance Boost: Monopar completed an underwritten public offering generating approximately $91.9 million in 2025, significantly strengthening its balance sheet, with current funds expected to support operations through December 31, 2027, ensuring smooth regulatory and commercial activities for ALXN1840.
- Significant R&D Progress: The NDA for ALXN1840 targeting Wilson disease is planned for submission in mid-2026, with recent presentations at EASL and ANA showcasing long-term efficacy and safety data from 255 patients, indicating statistically significant improvements in copper balance.
- Leadership Team Strengthening: Monopar appointed Susan Rodriguez as Chief Commercial and Strategy Officer to prepare for the potential launch of ALXN1840, further enhancing the company's competitive position in the Wilson disease treatment market.
- R&D Expense Control: R&D expenses for Q4 2025 were $3.9 million, significantly down from $9.9 million in Q4 2024, primarily due to the absence of one-time costs, while reflecting increased investments in personnel and clinical materials.
See More
